Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  5/18/2012
University of Alabama at Birmingham
mi
from
Birmingham, AL
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 5/18/2012
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  5/18/2012
Banner Sun Health Research Institute
mi
from
Phoenix, AZ
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 5/18/2012
Banner Sun Health Research Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  5/18/2012
University of California at Los Angeles
mi
from
Los Angeles, CA
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 5/18/2012
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  5/18/2012
University of California, San Diego
mi
from
San Diego, CA
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 5/18/2012
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  5/18/2012
Georgetown University
mi
from
Washington,
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 5/18/2012
Georgetown University
mi
from
Washington,
Click here to add this to my saved trials
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  5/18/2012
Emory University
mi
from
Atlanta, GA
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 5/18/2012
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  5/18/2012
Mount Sinai School of Medicine
mi
from
New York, NY
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 5/18/2012
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  5/18/2012
Duke University
mi
from
Durham, NC
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 5/18/2012
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  5/18/2012
Case Western Reserve Univ
mi
from
Cleveland, OH
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 5/18/2012
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  5/18/2012
Medical University of South Carolina
mi
from
Charleston, SC
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 5/18/2012
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  5/18/2012
University of Utah
mi
from
Salt Lake City, UT
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 5/18/2012
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Single Ascending Dose Study of BIIB037 in Subjects With Alzheimer's Disease
A Randomized, Blinded, Placebo-Controlled Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB037 in Subjects With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  6/28/2012
Glendale Adventist Medical Center
mi
from
Glendale, CA
Single Ascending Dose Study of BIIB037 in Subjects With Alzheimer's Disease
A Randomized, Blinded, Placebo-Controlled Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB037 in Subjects With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 6/28/2012
Glendale Adventist Medical Center
mi
from
Glendale, CA
Click here to add this to my saved trials
Single Ascending Dose Study of BIIB037 in Subjects With Alzheimer's Disease
A Randomized, Blinded, Placebo-Controlled Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB037 in Subjects With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  6/28/2012
MD Clinical
mi
from
Hallandale Beach, FL
Single Ascending Dose Study of BIIB037 in Subjects With Alzheimer's Disease
A Randomized, Blinded, Placebo-Controlled Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB037 in Subjects With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 6/28/2012
MD Clinical
mi
from
Hallandale Beach, FL
Click here to add this to my saved trials
Single Ascending Dose Study of BIIB037 in Subjects With Alzheimer's Disease
A Randomized, Blinded, Placebo-Controlled Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB037 in Subjects With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  6/28/2012
Compass Research LLC
mi
from
Orlando, FL
Single Ascending Dose Study of BIIB037 in Subjects With Alzheimer's Disease
A Randomized, Blinded, Placebo-Controlled Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB037 in Subjects With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 6/28/2012
Compass Research LLC
mi
from
Orlando, FL
Click here to add this to my saved trials
Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease
A Methodology Study To Evaluate The Acute Effects Of Donepezil On Regional Cerebral Perfusion And Cognition In Subjects With Amnestic MCI And Mild Alzheimer's Disease
Status: Enrolling
Updated:  7/5/2012
Pfizer Investigational Site
mi
from
Los Angeles, CA
Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease
A Methodology Study To Evaluate The Acute Effects Of Donepezil On Regional Cerebral Perfusion And Cognition In Subjects With Amnestic MCI And Mild Alzheimer's Disease
Status: Enrolling
Updated: 7/5/2012
Pfizer Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease
A Methodology Study To Evaluate The Acute Effects Of Donepezil On Regional Cerebral Perfusion And Cognition In Subjects With Amnestic MCI And Mild Alzheimer's Disease
Status: Enrolling
Updated:  7/5/2012
Pfizer Investigational Site
mi
from
Baltimore, MD
Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease
A Methodology Study To Evaluate The Acute Effects Of Donepezil On Regional Cerebral Perfusion And Cognition In Subjects With Amnestic MCI And Mild Alzheimer's Disease
Status: Enrolling
Updated: 7/5/2012
Pfizer Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease
A Methodology Study To Evaluate The Acute Effects Of Donepezil On Regional Cerebral Perfusion And Cognition In Subjects With Amnestic MCI And Mild Alzheimer's Disease
Status: Enrolling
Updated:  7/5/2012
Pfizer Investigational Site
mi
from
Cape Girardeau, MO
Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease
A Methodology Study To Evaluate The Acute Effects Of Donepezil On Regional Cerebral Perfusion And Cognition In Subjects With Amnestic MCI And Mild Alzheimer's Disease
Status: Enrolling
Updated: 7/5/2012
Pfizer Investigational Site
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease
A Methodology Study To Evaluate The Acute Effects Of Donepezil On Regional Cerebral Perfusion And Cognition In Subjects With Amnestic MCI And Mild Alzheimer's Disease
Status: Enrolling
Updated:  7/5/2012
Pfizer Investigational Site
mi
from
Pittsburgh, PA
Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease
A Methodology Study To Evaluate The Acute Effects Of Donepezil On Regional Cerebral Perfusion And Cognition In Subjects With Amnestic MCI And Mild Alzheimer's Disease
Status: Enrolling
Updated: 7/5/2012
Pfizer Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease
Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  7/27/2012
Parkway Medical Building
mi
from
Beachwood, OH
Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease
Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 7/27/2012
Parkway Medical Building
mi
from
Beachwood, OH
Click here to add this to my saved trials
Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days
Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days
Status: Enrolling
Updated:  7/30/2012
VA Puget Sound Health Care System
mi
from
Seattle, WA
Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days
Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days
Status: Enrolling
Updated: 7/30/2012
VA Puget Sound Health Care System
mi
from
Seattle, WA
Click here to add this to my saved trials
3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease
A 3-month Randomized, Double-Blind, Placebo-Controlled, Feasibility Study to Evaluate the Effects of MSDC-0160 on Brain Glucose Utilization, Cognition, Safety and Tolerability in Older Persons With Mild Alzheimer's Disease
Status: Enrolling
Updated:  7/31/2012
Rush Memorial University Medical Center
mi
from
Chicago, IL
3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease
A 3-month Randomized, Double-Blind, Placebo-Controlled, Feasibility Study to Evaluate the Effects of MSDC-0160 on Brain Glucose Utilization, Cognition, Safety and Tolerability in Older Persons With Mild Alzheimer's Disease
Status: Enrolling
Updated: 7/31/2012
Rush Memorial University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Thalidomide for Patients With Mild to Moderate Alzheimer's Disease
"Twenty-Four-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fixed Dose Regimens of Thalidomide and Placebo on CSF and Plasma Biomarkers in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  8/6/2012
Banner Sun Health Research Institute
mi
from
Sun City, AZ
Thalidomide for Patients With Mild to Moderate Alzheimer's Disease
"Twenty-Four-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fixed Dose Regimens of Thalidomide and Placebo on CSF and Plasma Biomarkers in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 8/6/2012
Banner Sun Health Research Institute
mi
from
Sun City, AZ
Click here to add this to my saved trials
Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC
An Exploratory, Open-label, Non-randomized Phase 0 Study to Evaluate [18F]-FMH3 by Positron Emission Tomography (PET) for Quantization of the Receptor Histamine-3 in Human
Status: Enrolling
Updated:  9/12/2012
The Institute for Neurodegenerative Disorders
mi
from
New Haven, CT
Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC
An Exploratory, Open-label, Non-randomized Phase 0 Study to Evaluate [18F]-FMH3 by Positron Emission Tomography (PET) for Quantization of the Receptor Histamine-3 in Human
Status: Enrolling
Updated: 9/12/2012
The Institute for Neurodegenerative Disorders
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated:  9/17/2012
Reserach Site
mi
from
Escondido, CA
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated: 9/17/2012
Reserach Site
mi
from
Escondido, CA
Click here to add this to my saved trials
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated:  9/17/2012
Clinical Research Facility
mi
from
San Diego, CA
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated: 9/17/2012
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated:  9/17/2012
Clinical Research Facility
mi
from
Fort Lauderdale, FL
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated: 9/17/2012
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated:  9/17/2012
Clinical Research Facility
mi
from
Atlanta, GA
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated: 9/17/2012
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated:  9/17/2012
Clinical Research Facility
mi
from
Evanston, IL
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated: 9/17/2012
Clinical Research Facility
mi
from
Evanston, IL
Click here to add this to my saved trials
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated:  9/17/2012
Clinical Research Facility
mi
from
Kansas City, KA
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated: 9/17/2012
Clinical Research Facility
mi
from
Kansas City, KA
Click here to add this to my saved trials
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated:  9/17/2012
Clinical Research Facility
mi
from
Detroit, MI
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated: 9/17/2012
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated:  9/17/2012
Clinical Research Facility
mi
from
Teaneck, NJ
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated: 9/17/2012
Clinical Research Facility
mi
from
Teaneck, NJ
Click here to add this to my saved trials
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated:  9/17/2012
Clinical Research Facility
mi
from
Bronx, NY
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated: 9/17/2012
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated:  9/17/2012
Clinical Research Facility
mi
from
Asheville, NC
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated: 9/17/2012
Clinical Research Facility
mi
from
Asheville, NC
Click here to add this to my saved trials
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated:  9/17/2012
Clinical Research Facility
mi
from
Akron, OH
A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Designed as a Randomized, Double-Blind, Multi-Center, Parallel Group, Placebo-Controlled Study
Status: Enrolling
Updated: 9/17/2012
Clinical Research Facility
mi
from
Akron, OH
Click here to add this to my saved trials
An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption
A Randomized, Open-label, 3-treatment Crossover Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption in Healthy Caucasian Male Adults
Status: Enrolling
Updated:  10/29/2012
California Clinical Trials/Parexel
mi
from
Glendale, CA
An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption
A Randomized, Open-label, 3-treatment Crossover Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption in Healthy Caucasian Male Adults
Status: Enrolling
Updated: 10/29/2012
California Clinical Trials/Parexel
mi
from
Glendale, CA
Click here to add this to my saved trials
Zolpidem CR and Hospitalized Patients With Dementia
Does Zolpidem CR Treatment Change Clinical Outcomes in Elderly Hospitalized Patients With Dementia- A Pilot Study
Status: Enrolling
Updated:  11/2/2012
Massachusetts General Hospital
mi
from
Boston, MA
Zolpidem CR and Hospitalized Patients With Dementia
Does Zolpidem CR Treatment Change Clinical Outcomes in Elderly Hospitalized Patients With Dementia- A Pilot Study
Status: Enrolling
Updated: 11/2/2012
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
VI-1121 for the Treatment Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  11/8/2012
Clinical Research Facility
mi
from
Santa Clara, CA
VI-1121 for the Treatment Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 11/8/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Click here to add this to my saved trials
VI-1121 for the Treatment Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  11/8/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
VI-1121 for the Treatment Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 11/8/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
VI-1121 for the Treatment Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  11/8/2012
Clinical Research Facility
mi
from
Louisville, KY
VI-1121 for the Treatment Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 11/8/2012
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
VI-1121 for the Treatment Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  11/8/2012
Clinical Research Facility
mi
from
Henderson, NV
VI-1121 for the Treatment Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 11/8/2012
Clinical Research Facility
mi
from
Henderson, NV
Click here to add this to my saved trials
VI-1121 for the Treatment Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  11/8/2012
Clinical Research Facility
mi
from
Newark, NJ
VI-1121 for the Treatment Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 11/8/2012
Clinical Research Facility
mi
from
Newark, NJ
Click here to add this to my saved trials
VI-1121 for the Treatment Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  11/8/2012
Clinical Research Facility
mi
from
New York, NY
VI-1121 for the Treatment Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 11/8/2012
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
VI-1121 for the Treatment Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  11/8/2012
Clinical Research Facility
mi
from
Ashville, NC
VI-1121 for the Treatment Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 11/8/2012
Clinical Research Facility
mi
from
Ashville, NC
Click here to add this to my saved trials
VI-1121 for the Treatment Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  11/8/2012
Clinical Research Facility
mi
from
Cleveland, OH
VI-1121 for the Treatment Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 11/8/2012
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
VI-1121 for the Treatment Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated:  11/8/2012
Clinical Research Facility
mi
from
Dallas, TX
VI-1121 for the Treatment Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease
Status: Enrolling
Updated: 11/8/2012
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/11/2012
Banner Alzheimer'S Institute
mi
from
Phoenix, AZ
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/11/2012
Banner Alzheimer'S Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/11/2012
University of California, Irvine
mi
from
Irvine, CA
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/11/2012
University of California, Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/11/2012
University of California, San Diego - Comprehensive Alzheimer's Program
mi
from
La Jolla, CA
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/11/2012
University of California, San Diego - Comprehensive Alzheimer's Program
mi
from
La Jolla, CA
Click here to add this to my saved trials
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/11/2012
University of Southern California
mi
from
Los Angeles, CA
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/11/2012
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/11/2012
Yale University
mi
from
New Haven, CT
Resveratrol for Alzheimer's Disease
Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/11/2012
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials